“Lung Cancer Talk”: A Review of Data from the ASCO 2020 Virtual Meeting : Episode 4

KRAS-Mutant NSCLC

Sep 1, 2020

Joshua M. Bauml, MD, Perelman School of Medicine
Hossein Borghaei, DO, MS, Fox Chase Center at Temple Health

Advancements in drugs targeting KRAS G12C mutations and incorporating AMG 510 and MRTX849 into clinical practice when treating mNSCLC.

Related Videos

Henry S. Park, MD, MPH

Expert on lung cancer

Expert on lung cancer

Anne Chiang, MD, PhD

Sarah Goldberg, MD, MPH

Ferdinandos Skoulidis, MD, PhD, MRCP

Amy L. Cummings, MD, PhD

Expert on lung cancer

Related Content

FDA Grants Priority Review to Repotrectinib for ROS1+ NSCLC

Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

Sitravatinib Plus Nivolumab Fails to Meet OS End Point in Nonsquamous NSCLC

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

OncLive Honors 12 Cancer Care Pioneers

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

FDA Grants Priority Review to Repotrectinib for ROS1+ NSCLC

Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

Sitravatinib Plus Nivolumab Fails to Meet OS End Point in Nonsquamous NSCLC

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

OncLive Honors 12 Cancer Care Pioneers

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

FDA Grants Priority Review to Repotrectinib for ROS1+ NSCLC

Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

Sitravatinib Plus Nivolumab Fails to Meet OS End Point in Nonsquamous NSCLC

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

OncLive Honors 12 Cancer Care Pioneers

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

Related Content

FDA

FDA Grants Priority Review to Repotrectinib for ROS1+ NSCLC

Jorge M. Mercado, MD; Stephen Kovacs, DO

Mercado and Kovacs Emphasize the Importance of Multidisciplinary Lung Cancer Screening and Management

Alan Sandler, MD

Sitravatinib Plus Nivolumab Fails to Meet OS End Point in Nonsquamous NSCLC

Luis E. Raez, MD, FACP, FCCP

Raez Reports Benefits of Liquid Biopsy in Newly Diagnosed NSCLC

March 16th 2023

Ann H. Partridge, MD, MPH

OncLive Honors 12 Cancer Care Pioneers

John V. Heymach, MD

AEGEAN Trial Demonstrates Benefit and Viability of Novel Perioperative Treatment Approach in NSCLC

Latest Conference Coverage

Medicaid Expansion Improves Survival in Pancreatic, Gastric Cancers, Potentially Reducing Disparities

Telephone-Based Weight Loss Program Is Effective for Breast Cancer Survivors

Pembrolizumab Plus Chemo With or Without Bevacizumab Maintains OS Benefit in Frontline Cervical Cancer

Minimally Invasive Distal Pancreatectomy Provides Effective Alternative in Resectable Pancreatic Cancer

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

OncNursingNews.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

2 Clarke Drive
Cranbury, NJ 08512

© 2023 MJH Life Sciences

All rights reserved.